We have observed
8 EP applications
Richard Charles Sewell
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after September 16, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR-GAMMA) FOR USE IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES
1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS
USE OF CXCR2 ANTAGONISTS FOR THE PREVENTION AND/OR TREATMENT OF CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY (CIPN)